Roche ' s Tecentriq Wins Fast FDA Review in Tough-to-Treat Breast Cancer Roche ' s Tecentriq Wins Fast FDA Review in Tough-to-Treat Breast Cancer

Swiss drugmaker Roche said on Tuesday its Tecentriq medicine will get a speedy review by U.S. regulators in a tough-to-treat form of breast cancer, as it seeks to be the first company to have its immunotherapy win approval in this indication.Reuters Health Information
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news